Maxim Group downgraded Galmed Pharmaceuticals (NASDAQ:GLMD) to "hold" from "buy" and removed its previous $14 price target after the company announced that top-line results from the ARRIVE trial did not meet its primary endpoint.Read More
H.C. Wainwright lowered its price target to Galmed Pharmaceuticals (NASDAQ:GLMD) to $13 from $22, citing enrollment delays in a Phase 2b NASH trial of aramchol. The stock closed at $4.13 on Wednesday.Read More
Maxim Group lowered its price target for Galmed Pharmaceuticals (NASDAQ:GLMD) to $9 from $24, citing a bearish biotech market environment, catalysts, and revisions to timelines, as well as other related assumptions. The stock was changing hands at $4.26 in Monday afternoon trading.
Analyst Jason Kolbert writes that the next major inflection point for Galmed is proof-of-concept data for Aramchol in nonalcoholic steatohepatitis (NASH) in 2018.Read More
H.C. Wainwright analyst, Ed Arce, has assumed coverage of Galmed Pharmaceuticals (NASDAQ:GLMD) with a “buy” rating and $22 price target. The stock closed at $4.44 on Friday.
Galmed is focused on the development of a sole drug candidate, aramchol, as a potentially disease-modifying treatment for nonalcoholic steatohepatitis (NASH).Read More